A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931

Control Clin Trials. 1997 Aug;18(4):286-300. doi: 10.1016/0197-2456(96)00116-x.

Abstract

A quality of life (QOL) endpoint supplemented standard clinical endpoints of survival, tumor response, and toxicity in a double-blind study conducted by the Cancer and Leukemia Group B (CALGB) where 291 patients with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive cisplatin/vinblastine with either hydrazine sulfate (HS) or placebo. The difficulties associated with the analysis of the longitudinal QOL data, and the contributions that the QOL endpoint made to the understanding of treatment differences, will be the focus of this paper.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / mortality*
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Double-Blind Method
  • Drug Administration Schedule
  • Humans
  • Hydrazines / administration & dosage
  • Hydrazines / adverse effects
  • Longitudinal Studies
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / mortality*
  • Proportional Hazards Models
  • Quality of Life*
  • Quality-Adjusted Life Years
  • Vinblastine / administration & dosage
  • Vinblastine / adverse effects

Substances

  • Hydrazines
  • hydrazine
  • Vinblastine
  • Cisplatin